Literature DB >> 24020980

Adeno-associated virus enhances wild-type and oncolytic adenovirus spread.

Eduardo Laborda1, Cristina Puig-Saus, Manel Cascalló, Miguel Chillón, Ramon Alemany.   

Abstract

The contamination of adenovirus (Ad) stocks with adeno-associated viruses (AAV) is usually unnoticed, and it has been associated with lower Ad yields upon large-scale production. During Ad propagation, AAV contamination needs to be detected routinely by polymerase chain reaction without symptomatic suspicion. In this study, we describe that the coinfection of either Ad wild type 5 or oncolytic Ad with AAV results in a large-plaque phenotype associated with an accelerated release of Ad from coinfected cells. This accelerated release was accompanied with the expected decrease in Ad yields in two out of three cell lines tested. Despite this lower Ad yield, coinfection with AAV accelerated cell death and enhanced the cytotoxicity mediated by Ad propagation. Intratumoral coinjection of Ad and AAV in two xenograft tumor models improved antitumor activity and mouse survival. Therefore, we conclude that accidental or intentional AAV coinfection has important implications for Ad-mediated virotherapy.

Entities:  

Mesh:

Year:  2013        PMID: 24020980      PMCID: PMC3869535          DOI: 10.1089/hgtb.2013.124

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  38 in total

1.  The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants.

Authors:  A E Tollefson; J S Ryerse; A Scaria; T W Hermiston; W S Wold
Journal:  Virology       Date:  1996-06-01       Impact factor: 3.616

2.  Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors.

Authors:  Javier García-Castro; Jesús Martínez-Palacio; Rosa Lillo; Félix García-Sánchez; Ramón Alemany; Luis Madero; Juan A Bueren; Manuel Ramírez
Journal:  Cancer Gene Ther       Date:  2005-04       Impact factor: 5.987

3.  Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.

Authors:  G Coukos; A Makrigiannakis; E H Kang; D Caparelli; I Benjamin; L R Kaiser; S C Rubin; S M Albelda; K L Molnar-Kimber
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

4.  Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.

Authors:  Oh-Joon Kwon; Eunah Kang; Sungwan Kim; Chae-Ok Yun
Journal:  J Control Release       Date:  2011-06-14       Impact factor: 9.776

5.  Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.

Authors:  Oliver J Müller; Barbara Leuchs; Sven T Pleger; Dirk Grimm; Wolfgang-M Franz; Hugo A Katus; Jürgen A Kleinschmidt
Journal:  Cardiovasc Res       Date:  2006-01-31       Impact factor: 10.787

6.  Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector.

Authors:  H Sauthoff; S Heitner; W N Rom; J G Hay
Journal:  Hum Gene Ther       Date:  2000-02-10       Impact factor: 5.695

7.  Inhibition of adenovirus cytotoxicity, replication, and E2a gene expression by adeno-associated virus.

Authors:  X J Jing; V Kalman-Maltese; X Cao; Q Yang; J P Trempe
Journal:  Virology       Date:  2001-12-05       Impact factor: 3.616

8.  Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus.

Authors:  Konstantin Doronin; Karoly Toth; Mohan Kuppuswamy; Peter Krajcsi; Ann E Tollefson; William S M Wold
Journal:  Virology       Date:  2003-01-20       Impact factor: 3.616

Review 9.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

10.  Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.

Authors:  Harald Sauthoff; Teona Pipiya; Sheila Heitner; Shu Chen; Robert G Norman; William N Rom; John G Hay
Journal:  Hum Gene Ther       Date:  2002-10-10       Impact factor: 5.695

View more
  4 in total

1.  Persistent viremia by a novel parvovirus in a slow loris (Nycticebus coucang) with diffuse histiocytic sarcoma.

Authors:  Marta Canuti; Cathy V Williams; Sashi R Gadi; Maarten F Jebbink; Bas B Oude Munnink; Seyed Mohammad Jazaeri Farsani; John M Cullen; Lia van der Hoek
Journal:  Front Microbiol       Date:  2014-12-01       Impact factor: 5.640

Review 2.  Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.

Authors:  Zhongbing Qi; Xiangyu Long; Jiyan Liu; Ping Cheng
Journal:  Front Cell Neurosci       Date:  2022-09-09       Impact factor: 6.147

Review 3.  Designing and building oncolytic viruses.

Authors:  Justin Maroun; Miguel Muñoz-Alía; Arun Ammayappan; Autumn Schulze; Kah-Whye Peng; Stephen Russell
Journal:  Future Virol       Date:  2017-03-31       Impact factor: 1.831

Review 4.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.